Filing Flows › Health Care › Alpha Teknova (TKNO)
Alpha Teknova (TKNO) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Alpha Teknova (TKNO) Q3 2026 earnings results →
Q3 2026 Revenue up 22% year over year to $12.7M · 27¢ of every $1 of revenue lost · operating margin -25.2%
Alpha Teknova made $12.7M in Q3 2026 (+22% Y/Y): Lab Essentials $9.0M, Clinical Solutions $3.2M, Other Product $502K. Operating margin -25.2%, net loss $3.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $12.7M in Q3 2026, up 22% year over year and up 4% from the previous quarter. Lab Essentials was the largest line at 71% of revenue. Clinical Solutions added $1.5M year over year (up 86%), 65% of the total change.
Gross margin was 38.0%, up 7.3 points from Q3 2025. Operating costs exceeded revenue by $3.2M, an operating margin of -25.2%. Operating expenses grew 11% against revenue growth of 22%. The fastest-growing cost line was Sales & marketing (+34%). The quarter ended with a net loss of $3.5M, wider than the previous quarter's $3.2M loss.
Operating cash flow was −$1.3M. Non-cash charges added back $1.6M of depreciation and amortization and $612K of share-based compensation. Capital expenditures of $120K exceeded it, leaving free cash flow of −$1.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $12.7M | +22% | -25.2% | −$3.5M | −$1.3M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $12.2M | +18% | -23.7% | −$3.2M | −$471K |
| Q1 2026 | 10-Q | May 7, 2026 | $11.1M | +13% | -38.8% | −$4.6M | −$3.4M |
| Q4 2025 | 10-K | Mar 2, 2026 | $10.0M | +8% | -46.2% | −$4.8M | −$462K |
| Q3 2025 | 10-Q | Nov 7, 2025 | $10.5M | +9% | -38.4% | −$4.3M | −$2.0M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $10.3M | +7% | -32.9% | −$3.6M | −$2.1M |
| Q1 2025 | 10-Q | May 9, 2025 | $9.8M | +5% | -50.7% | −$4.6M | −$4.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Alpha Teknova
Teknova manufactures its products at its Hollister, California headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister, California.
In its own words, from its 10-Q, filed Aug 6, 2026.
Alpha Teknova against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +22% against the peers' median +2%. Operating margin: -25.2% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
Source: Alpha Teknova 10-Q on SEC EDGAR · CIK 1850902 · In Vitro & In Vivo Diagnostic Substances
13F: who owns TKNO and who is buying
More on TKNO
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results